DELTICOM-B2B
Users of Goodride, Star Performer or Nankang tyres will be more relaxed when it comes to their wallets in the future: Many of Delticom’s B2B shops now offer a lifetime warranty on its Star Performer tires and other Delticom house brands - giving its dealers strong selling points. The warranty is valid in Germany, Austria, Switzerland, Netherlands, Sweden, Denmark, France, Spain, Italy, Poland, Portugal and Finland. In the event of manufacturing or material defects and even irreparable damage due to everyday use the tire will either be replaced at no cost or big discounts will be offered. The compensation claim depends on the remaining tread depth. For example, defective tires with a remaining tread depth of six millimeters or more will be replaced with new ones, or customers receive a discount of up to 80 percent of the current price on the day the warranty claim is made.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181030005757/en/
"Current market monitors show a trend to increasing demand for cheap tires. Star Performer, Goodride and Nankang perfectly complement a dealer's portfolio", explains Thorsten Orbach, Head of Dealer Business at Delticom B2B. "Dealers can offer price-conscious end customers, who value an excellent cost benefit ratio above all else, an excellent alternative with an attractive margin for themselves at the same time. With the lifetime guarantee, we also generate business for our dealers with Goodride, Star Performer and Nankang tires.“
Additional information about the lifetime warranty can be found in the German online shop under the following links:
https://www.autoreifenonline.de/Goodride-Reifengarantie-lifetime.html
https://www.autoreifenonline.de/Star-Performer-Reifengarantie-lifetime.html
https://www.autoreifenonline.de/Nankang-Reifengarantie-lifetime.html
About Autoreifenonline.de
Autoreifenonline.de is the
exclusive German online shop for garages, dealers, wholesalers and
service/installation stations from Delticom AG with tires of all types
and car accessories. With more than 15 years experience in online tire
business, the B2B professional team from Autoreifenonline.de offers
their business customers an outstanding range of car and motorcycle
tires of all makes and sizes for all vehicle types, light truck and
truck tires, bus tires, special tires, complete wheels, car spare parts
and accessories, engine oil and batteries. Dealers not only benefit from
good purchasing conditions, but also time-saving tire search functions
in the online shop, high availability, reliable delivery thanks to their
own warehouses, as well as easy registration and use without any hidden
costs - from the very first tire on.
Online shops for dealers and garages in Germany, Austria and Switzerland : www.autoreifenonline.de , www.autoreifenonline.at , www.autoreifenonline.ch and 24 other countries.
Information about the business : www.delti.com
Tire tests : www.reifentest.com
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005757/en/
Contact:
Press contact insignis Agentur für Kommunikation GmbH (GPRA) Henning Jahns Tel.: +49-511-132214-14 Fax: +49-511-132214-99 delticom@insignis.de or Delticom AG Anne Lena Peters Tel.: +49-511-93634-8909 Fax: +49-511-93634-8301 anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom